These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22343817)

  • 1. Is it possible for FDA regulatory scientists and industry scientists to work together?
    Woosley RL
    Clin Pharmacol Ther; 2012 Mar; 91(3):390-2. PubMed ID: 22343817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL; Myers RT; Goodsaid F
    Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
    Vladeck DC
    Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
    [No Abstract]   [Full Text] [Related]  

  • 5. Re-engineering drug discovery and development.
    FitzGerald GA
    LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FDA and congress: differing agendas?
    Lipman AG
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):116-7. PubMed ID: 20504131
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular diagnostics: an FDA perspective.
    Ardekani AM; Petricoin EF; Hackett JL
    Expert Rev Mol Diagn; 2003 Mar; 3(2):129-40. PubMed ID: 12647991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of regulatory science on global public health.
    Patel M; Miller MA
    Kaohsiung J Med Sci; 2012 Jul; 28(7 Suppl):S5-9. PubMed ID: 22871603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The critical path initiative: leveraging collaborations to enhance regulatory science.
    Barratt RA; Bowens SL; McCune SK; Johannessen JN; Buckman SY
    Clin Pharmacol Ther; 2012 Mar; 91(3):380-3. PubMed ID: 22343813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming regulatory science 2012: making a difference.
    Goodman JL
    Clin Pharmacol Ther; 2012 Mar; 91(3):375-7. PubMed ID: 22343811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceuticals and medical devices: FDA oversight.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
    [No Abstract]   [Full Text] [Related]  

  • 13. Current FDA directives for promoting public health.
    Hayes AH
    Am J Hosp Pharm; 1982 Mar; 39(3):427-31. PubMed ID: 7072727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knowledge management for efficient quantitative analyses during regulatory reviews.
    Krudys K; Li F; Florian J; Tornoe C; Chen Y; Bhattaram A; Jadhav P; Neal L; Wang Y; Gobburu J; Lee PI
    Expert Rev Clin Pharmacol; 2011 Nov; 4(6):697-703. PubMed ID: 22111855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dangers of direct-to-consumer advertising exposed again.
    Lancet Oncol; 2015 Apr; 16(4):349. PubMed ID: 25846082
    [No Abstract]   [Full Text] [Related]  

  • 17. New law aims to distance the FDA from the drug industry.
    Lenzer J
    BMJ; 2005 May; 330(7500):1106. PubMed ID: 15891225
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA review divisions: performance levels and the impact on drug sponsors.
    Milne CP; Kaitin KI
    Clin Pharmacol Ther; 2012 Mar; 91(3):393-404. PubMed ID: 22336592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA proposes more stringent pediatric-use labeling of prescription drug products.
    Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyberpharmacies and the role of the US Food And Drug Administration.
    Henney JE
    J Med Internet Res; 2001; 3(1):E3. PubMed ID: 11720945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.